title: Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta-chain that acts synergistically with humanized anti-TAC.
abstract: Mik beta 1 is a mouse mAb directed at the beta-subunit of the human IL-2R (Tac) that inhibits IL-2 binding and inhibits IL-2 induction of large granular lymphocytes (LGL). Mik beta 1 alone does not inhibit IL-2-induced T-cell proliferation, but acts synergistically with anti-Tac to inhibit IL-2-induced proliferation of activated T cells. To evaluate these effects for possible therapy in humans, we constructed two humanized Mik beta 1 antibodies by combining the complementarity-determining regions of the murine antibody with human framework and constant regions. Compared with murine Mik beta 1, the two humanized Mik beta 1 antibodies, which differ in their degree of humanization, had similar affinities for IL-2R beta. The murine Mik beta 1 and one of the humanized Mik beta 1 antibodies were equivalent in competing for IL-2 binding to IL-2R beta and inhibiting IL-2 induction of LGL cytotoxicity. The activity of the second humanized antibody was significantly reduced. The three Mik beta 1 antibodies act synergistically to varying degrees with humanized anti-Tac to prevent IL-2-induced proliferation of activated T cells. This capacity to synergize paralleled their abilities to inhibit IL-2 binding. In addition, both humanized antibodies directed antibody-dependent cell-mediated cytotoxicity. We hope that humanized Mik beta 1 in combination with humanized anti-Tac will provide a new immunosuppressive therapy for the treatment of autoimmune diseases, graft-versus-host disease, and prevention of allograft rejection.
authors.affiliation: Roche Research Center, Hoffmann-LaRoche, Inc., Nutley, NJ 07110.
authors.forename: J
authors.initials: J
authors.lastname: Hakimi
authors.forename: V C
authors.initials: VC
authors.lastname: Ha
authors.forename: P
authors.initials: P
authors.lastname: Lin
authors.forename: E
authors.initials: E
authors.lastname: Campbell
authors.forename: M K
authors.initials: MK
authors.lastname: Gately
authors.forename: M
authors.initials: M
authors.lastname: Tsudo
authors.forename: P W
authors.initials: PW
authors.lastname: Payne
authors.forename: T A
authors.initials: TA
authors.lastname: Waldmann
authors.forename: A J
authors.initials: AJ
authors.lastname: Grant
authors.forename: W H
authors.initials: WH
authors.lastname: Tsien
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D000920:Antibody-Dependent Cell Cytotoxicity; D001483:Base Sequence; D003001:Cloning, Molecular; D006801:Humans; D007376:Interleukin-2 / Q000037:antagonists & inhibitors; D051379:Mice; D008969:Molecular Sequence Data; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins